Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2023-04-17 Earnings Release
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
Earnings Release 2023
Earnings Release Classification · 100% confidence The document provides preliminary financial highlights for Q1 2023, including revenue, EBIT, and sales figures, and confirms the full-year outlook. This content structure—presenting key figures for a recent period and updating guidance—is characteristic of an Earnings Release (ER). Although it mentions the full Q1 interim report will be published later (May 9th), the current document itself is the initial announcement of the results, not the comprehensive report (IR) or the announcement of the report's publication (RPA). Document length (4984 chars) is substantial enough to contain key figures, making it more than just a simple announcement of an attachment. Q1 2023
2023-04-17 English
ALK announces preliminary Q1 figures and confirms its full-year revenue and earnings outlook
Earnings Release Classification · 95% confidence The document is an announcement of preliminary financial results for the first quarter of 2023. It highlights key financial metrics (revenue growth, EBIT) and confirms full-year guidance. Crucially, it explicitly states that the full quarterly report will be published on a later date (May 9, 2023) and provides a link to the current announcement as an attachment. Given the focus on preliminary highlights and the announcement of future report publication, it fits the definition of an Earnings Release (ER). Q1 2023
2023-04-17 Danish
ALK announces preliminary Q1 figures and confirms its full-year revenue and earnings outlook
Earnings Release Classification · 100% confidence The document is a company release announcing preliminary Q1 2023 financial figures and confirming the full-year outlook. It explicitly states that the full interim report will be published on a later date (9 May 2023). Because it provides key financial highlights and outlook updates rather than the full report, and is not a mere announcement of a report's availability, it fits the definition of an Earnings Release (ER). Q1 2023
2023-04-17 English
Director's Dealing 2023
Director's Dealing Classification · 100% confidence The document is titled "Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer" (Reporting of management transactions in ALK-Abelló A/S' B-shares and related securities). It explicitly references Article 19 of the EU Market Abuse Regulation (MAR) and details transactions (delivery of performance shares and final allocation of stock options) by senior management ('Adm. direktør' and 'Direktionsmedlem'). This type of mandatory disclosure concerning personal share transactions by directors and executives is specifically classified as Director's Dealing.
2023-03-02 Danish
Remuneration Information 2023
Remuneration Information Classification · 99% confidence The document explicitly reports on 'transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff' and cites 'article 19 in Regulation (EU) No 596/2014... on market abuse'. This type of filing, detailing personal share transactions by directors and executives (insider trades), directly corresponds to the definition of Director's Dealing. The document mentions the final allocation of share options and delivery of performance shares, which are forms of insider transactions. Therefore, the appropriate code is DIRS.
2023-03-02 English
Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
Director's Dealing Classification · 95% confidence The document is a notification regarding transactions by company management (ledelsens transaktioner) involving shares and share options, specifically referencing EU Market Abuse Regulation (MAR) Article 19. This is a standard disclosure for director/executive dealings. While it mentions an attached file, the primary purpose of the text is to report the specific nature of the management's share-based transactions, which aligns with the 'Director's Dealing' category.
2023-03-02 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.